Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective-Reference-Cited by-同舟云学术

Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective

Published:2016-06-16 Issue:11 Volume:19 Page:1061-1074
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Jakubowiak Andrzej J.¹,Campioni Marco²,Benedict Ágnes³,Houisse Ivan³,Tichy Eszter³,Giannopoulou Andromachi²,Aggarwal Sanjay K.⁴,Barber Beth L.⁴,Panjabi Sumeet⁵

Affiliation:

1. Myeloma Program, University of Chicago, Chicago, IL, USA;

2. Global Health Economics, Amgen (Europe) GmbH, Zug, Switzerland;

3. Modeling and Simulation, Evidera, Budapest, Hungary;

4. Global Development, Amgen Inc., Thousand Oaks, CA, USA;

5. Global Health Economics, Amgen Inc. San Francisco, CA, USA

Funder

Amgen

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2016.1194278

Reference58 articles.

1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr. Accessed March 28, 2016

2. Multiple Myeloma

3. SEER. Surveillance, Epidemiology, and End Results Program. Stat Fact Sheets: Myeloma. Bethesda, Maryland: National Cancer Institute; 2016. http://seer.cancer.gov/statfacts/html/mulmy.html. Accessed March 28, 2016

4. Dimopoulos MA, Lonial S, White D, et al. Eloquent-2 update: a phase 3, randomized, open-label study of elotuzumab in combination with lenalidomide/dexamethasone in patients with relapsed/refractory multiple myeloma - 3-year safety and efficacy follow-up. ASH Meeting, Presented by Meletios Dimopolous. Orlando, FL; December 5th, 2015

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Systematic Review of Modeling Approaches to Evaluate Treatments for Relapsed Refractory Multiple Myeloma: Critical Review and Considerations for Future Health Economic Models;PharmacoEconomics;2024-06-25

2. Modeling First-Line Daratumumab Use for Newly Diagnosed, Transplant-Ineligible, Multiple Myeloma: A Cost-Effectiveness and Risk Analysis for Healthcare Payers;PharmacoEconomics - Open;2024-06-20

3. Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review;Clinical Lymphoma Myeloma and Leukemia;2023-06

4. The Zero-Price Conundrum: Exploration of Scenarios Where a Clinically Effective New Drug Might Not Be Cost-Effective at Zero Price;Value in Health;2023-03

5. Systematic literature review of health economic models developed for multiple myeloma to support future analyses;Journal of Medical Economics;2023-01-09